Medtronic (MDT) – Research Analysts’ Weekly Ratings Updates

Medtronic (NYSE: MDT) recently received a number of ratings updates from brokerages and research firms:

• 9/3/2026 – Medtronic had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 9/3/2026 – Medtronic had its “buy” rating reaffirmed by UBS Group AG. They now have a $110.00 price target on the stock.
• 9/2/2026 – Medtronic was given a new $115.00 price target by Mizuho.
• 9/2/2026 – Medtronic had its price target raised by Bank of America Corporation from $95.00 to $110.00. They now have a “buy” rating on the stock.
• 9/2/2026 – Medtronic had its price target raised by Wells Fargo & Company from $102.00 to $104.00. They now have an “overweight” rating on the stock.
• 9/2/2026 – Medtronic had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $99.00 price target on the stock, up from $86.00.
• 9/2/2026 – Medtronic had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $118.00 price target on the stock.
• 9/2/2026 – Medtronic had its price target raised by Robert W. Baird from $91.00 to $100.00. They now have a “neutral” rating on the stock.
• 9/2/2026 – Medtronic had its price target raised by Stifel Nicolaus from $80.00 to $95.00. They now have a “hold” rating on the stock.
• 9/1/2026 – Medtronic had its price target raised by BTIG Research from $91.00 to $100.00. They now have a “buy” rating on the stock.
• 8/28/2026 – Medtronic had its price target raised by TD Cowen from $100.00 to $110.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Medtronic had its price target raised by Needham & Company LLC from $101.00 to $114.00. They now have a “buy” rating on the stock.
• 8/18/2026 – Medtronic had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 8/18/2026 – Medtronic had its “buy” rating reaffirmed by BTIG Research. They now have a $91.00 price target on the stock.
• 8/10/2026 – Medtronic had its “neutral” rating reaffirmed by Piper Sandler.
• 7/28/2026 – Medtronic was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $100.00 price target on the stock, up from $85.00.
• 7/18/2026 – Medtronic was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/13/2026 – Medtronic had its “buy” rating reaffirmed by BTIG Research. They now have a $91.00 price target on the stock.
• 7/10/2026 – Medtronic had its price target lowered by TD Cowen from $119.00 to $100.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Medtronic was given a new $105.00 price target by Evercore Inc.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be paid a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.2%. Medtronic’s dividend payout ratio is presently 70.94%.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the sale, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.27% of the company’s stock.

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).